Feedback / Questions
ARB202 - Arbele
https://www.prnewswire.com/news-releases/arbele-announces-phase-1-first-in-human-study-of-cdh17xcd3-bispecific-t-cell-engager-for-treatment-of-gastrointestinal-cancers-301602166.html
Aug 10, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next